Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study.
Bhatt DL, Chew DP, Grines C, Mukherjee D, Leesar M, Gilchrist IC, Corbelli JC, Blankenship JC, Eres A, Steinhubl S, Tan WA, Resar JR, AlMahameed A, Abdel-Latif A, Tang WH, Brennan D, McErlean E, Hazen SL, Topol EJ.
Bhatt DL, et al. Among authors: hazen sl.
Am Heart J. 2007 Jul;154(1):137-43. doi: 10.1016/j.ahj.2007.03.029.
Am Heart J. 2007.
PMID: 17584566
Clinical Trial.